AbbVie recently announced that China’s National Medical Products Administration (NMPA) has approved
READ MORE 2022-03-11News List
AbbVie's oral JAK inhibitor Rinvoq (upatinib) approved by NMPA
Genentech’s Evrysdi (risdiplam) Granted FDA Priority Review for Treatment of Pre-Symptomatic Babies Under 2 Months of Age With Spinal Muscular Atrophy (SMA)
Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (
READ MORE 2022-02-10
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention
ViiV Healthcare announced that the US Food and Drug Administration (FDA) approvedApretude, the first
READ MORE 2021-12-22
Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
Novartis’ asciminib hasoutperformedPfizer’s Bosulif in a phase 3 chronic myeloid leukemia (CML) stud
READ MORE 2021-11-01
Hengrui announces new drug SHR7280
On October 11, 2021, Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that SHR0302, for the treat
READ MORE 2021-10-15
FDA Grants Breakthrough Therapy Designation to Merck’s Novel HIF-2α Inhibitor MK-6482 for Treatment of Certain Patients With Von Hippel-Lindau Disease- Associated Renal Cell Carcinoma
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S.
READ MORE 2021-09-07
Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis
August 17, 2021 – Novartis today announced that the China National Medical Products Administration (
READ MORE 2021-08-22
Bayer’s new symptomatic chronic heart failure treatment Verquvo™ (vericiguat) approved in EU
Berlin, Germany, July 21, 2021– The European Commission has granted marketing authorization in the E
READ MORE 2021-07-26
USFDA approves KIT inhibitor Ayvakit (Avatinib)
CStone's partner Blueprint Medicines recently announced that the U.S. Food and Drug Administrati
READ MORE 2021-06-24
AbbVie Presents New Late-Breaking Data Analyses Showing Risankizumab (SKYRIZI®) Achieves Clinical Remission and Endoscopic Response at Week 12 in Patients with Moderate to Severe Crohn's Disease
Late-breaking data analyses presented by AbbVie (NYSE: ABBV) at Digestive Disease Week®(DDW) Virtual
READ MORE 2021-06-01